Microbiome in Behcet's syndrome.
暂无分享,去创建一个
[1] G. Hatemi,et al. Vascular Behçet syndrome: from pathogenesis to treatment , 2022, Nature Reviews Rheumatology.
[2] Hyon Ju Park,et al. Behcet disease: an undifferentiating and complex vasculitis , 2022, Postgraduate medicine.
[3] Z. Zádori,et al. Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain. , 2022, Pharmacology & therapeutics.
[4] D. Roccatello,et al. The role of bacteria and viruses in Behçet syndrome: Should we move towards new paradigms? , 2022, Autoimmunity reviews.
[5] W. Robinson,et al. Clonal IgA and IgG autoantibodies from individuals at risk for rheumatoid arthritis identify an arthritogenic strain of Subdoligranulum , 2022, Science Translational Medicine.
[6] A. Kurilshikov,et al. Gut microbiome dysbiosis is associated with increased mortality after solid organ transplantation , 2022, Science Translational Medicine.
[7] Anna Christovich,et al. Gut Microbiota, Leaky Gut, and Autoimmune Diseases , 2022, Frontiers in Immunology.
[8] Xing He,et al. Findings on the Relationship Between Intestinal Microbiome and Vasculitis , 2022, Frontiers in Cellular and Infection Microbiology.
[9] T. Iqbal,et al. Gut microbiome and autoimmune disorders. , 2022, Clinical and experimental immunology.
[10] G. Hatemi,et al. Behçet's syndrome: one year in review 2022. , 2022, Clinical and experimental rheumatology.
[11] E. Miyauchi,et al. The impact of the gut microbiome on extra-intestinal autoimmune diseases , 2022, Nature Reviews Immunology.
[12] D. Mozaffarian,et al. Association of Trimethylamine N-Oxide and Metabolites With Mortality in Older Adults , 2022, JAMA network open.
[13] A. Fateh,et al. Interaction between Clostridium species and microbiota to progress immune regulation. , 2022, Acta microbiologica et immunologica Hungarica.
[14] D. Ojcius,et al. Gut barrier disruption and chronic disease , 2022, Trends in Endocrinology & Metabolism.
[15] A. Arcangeli,et al. A unique circulating miRNA profile highlights thrombo-inflammation in Behçet’s syndrome , 2021, Annals of the Rheumatic Diseases.
[16] S. Baldovino,et al. Vedolizumab for the Management of Refractory Behçet’s Disease: From a Case Report to New Pieces of Mosaic in a Complex Disease , 2021, Frontiers in Immunology.
[17] H. Direskeneli,et al. Pathogenesis of Behçet's Syndrome: Genetic, Environmental and Immunological Factors , 2021, Frontiers in Medicine.
[18] N. Taddei,et al. Neutrophil‐mediated mechanisms of damage and in‐vitro protective effect of colchicine in non‐vascular Behçet’s syndrome , 2021, Clinical and experimental immunology.
[19] A. Kijlstra,et al. Changes in the Gut Microbiome Contribute to the Development of Behcet’s Disease via Adjuvant Effects , 2021, Frontiers in Cell and Developmental Biology.
[20] C. Suh,et al. Eubacterium rectale Attenuates HSV-1 Induced Systemic Inflammation in Mice by Inhibiting CD83 , 2021, Frontiers in Immunology.
[21] D. Mozaffarian,et al. Association of Trimethylamine N-Oxide and Related Metabolites in Plasma and Incident Type 2 Diabetes , 2021, JAMA network open.
[22] Sun Park,et al. Alteration of the Fecal but Not Salivary Microbiome in Patients with Behçet’s Disease According to Disease Activity Shift , 2021, Microorganisms.
[23] G. Wallace,et al. Behçet’s Disease—Do Microbiomes and Genetics Collaborate in Pathogenesis? , 2021, Frontiers in Immunology.
[24] N. Mizuki,et al. Changes in the proportion of clinical clusters contribute to the phenotypic evolution of Behçet’s disease in Japan , 2021, Arthritis Research & Therapy.
[25] J. Guan,et al. Cluster analysis of phenotypes of patients with Behçet’s syndrome: a large cohort study from a referral center in China , 2020, Arthritis Research & Therapy.
[26] D. Dordević,et al. Hydrogen sulfide toxicity in the gut environment: Meta-analysis of sulfate-reducing and lactic acid bacteria in inflammatory processes , 2020, Journal of advanced research.
[27] R. Moots,et al. A Darwinian View of Behçet's Disease , 2015, Rheumatology and immunology research.
[28] Samir A. Shah,et al. Immunoglobulin A Targets a Unique Subset of the Microbiota in Inflammatory Bowel Disease. , 2020, Cell host & microbe.
[29] F. Sofi,et al. Butyrate Rich Diets Improve Redox Status and Fibrin Lysis in Behçet's Syndrome. , 2020, Circulation research.
[30] Ç. Ergin,et al. Succinivibrionaceae is dominant family in fecal microbiota of Behçet’s Syndrome patients with uveitis , 2020, PloS one.
[31] A. Moya,et al. Intestinal microbiota composition of patients with Behçet's disease: differences between eye, mucocutaneous and vascular involvement. The Rheuma-BIOTA study. , 2020, Clinical and experimental rheumatology.
[32] N. D. de Boer,et al. Gut Microbiota-driven Drug Metabolism in Inflammatory Bowel Disease , 2020, Journal of Crohn's & colitis.
[33] Malbert R. C. Rogers,et al. Behçet's Disease Under Microbiotic Surveillance? A Combined Analysis of Two Cohorts of Behçet's Disease Patients , 2020, Frontiers in Immunology.
[34] D. Seals,et al. Trimethylamine-N-Oxide Promotes Age-Related Vascular Oxidative Stress and Endothelial Dysfunction in Mice and Healthy Humans , 2020, Hypertension.
[35] E. Silvestri,et al. Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet’s phenotype: a multicentre study , 2020, Annals of the Rheumatic Diseases.
[36] P. Turnbaugh,et al. Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response , 2020, Nature Reviews Rheumatology.
[37] Oliver Fiehn,et al. A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors , 2020, Cell.
[38] M. Osman,et al. Global disparities in faecal microbiota transplantation research. , 2020, The lancet. Gastroenterology & hepatology.
[39] S. Turroni,et al. Modulation of gut microbiota through nutritional interventions in Behçet’s syndrome patients (the MAMBA study): study protocol for a randomized controlled trial , 2019, Trials.
[40] S. Ohno,et al. Alteration of oral flora in Mongolian patients with Behçet's disease: a multicentre study. , 2020, Clinical and experimental rheumatology.
[41] W. Dahl,et al. Diet, nutrients and the microbiome. , 2020, Progress in molecular biology and translational science.
[42] Y. Tao,et al. Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome , 2019, Signal Transduction and Targeted Therapy.
[43] S. Turner,et al. Microbiota-Derived Short-Chain Fatty Acids Promote the Memory Potential of Antigen-Activated CD8+ T Cells. , 2019, Immunity.
[44] Anukriti Sharma,et al. Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response? , 2019, Clinical pharmacology and therapeutics.
[45] N. Oezguen,et al. Microbiota stratification identifies disease-specific alterations in neuro-Behçet's disease and multiple sclerosis. , 2019, Clinical and experimental rheumatology.
[46] G. Hatemi,et al. Behçet's Syndrome as a Model of Thrombo-Inflammation: The Role of Neutrophils , 2019, Front. Immunol..
[47] E. Alpsoy,et al. Behçet’s Disease: An Overview of Etiopathogenesis , 2019, Front. Immunol..
[48] A. R. Moravejolahkami,et al. Synbiotic Supplementation May Relieve Anterior Uveitis, an Ocular Manifestation in Behcet’s Syndrome , 2019, The American journal of case reports.
[49] Y. Ghasemi,et al. Prebiotics: Definition, Types, Sources, Mechanisms, and Clinical Applications , 2019, Foods.
[50] N. Taddei,et al. Behçet’s syndrome as a tool to dissect the mechanisms of thrombo‐inflammation: clinical and pathogenetic aspects , 2018, Clinical and experimental immunology.
[51] E. Silvestri,et al. Efficacy of the anti-IL 17 secukinumab in refractory Behçet's syndrome: A preliminary study. , 2019, Journal of autoimmunity.
[52] A. Gasbarrini,et al. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases , 2019, Microorganisms.
[53] J. Shimizu,et al. Relative abundance of Megamonas hypermegale and Butyrivibrio species decreased in the intestine and its possible association with the T cell aberration by metabolite alteration in patients with Behcet’s disease (210 characters) , 2019, Clinical Rheumatology.
[54] M. Fischbach,et al. Microbial Transplantation With Human Gut Commensals Containing CutC Is Sufficient to Transmit Enhanced Platelet Reactivity and Thrombosis Potential , 2018, Circulation research.
[55] Chunyan Wu,et al. A metagenomic study of the gut microbiome in Behcet’s disease , 2018, Microbiome.
[56] Min-jung Park,et al. Attenuation of Rheumatoid Inflammation by Sodium Butyrate Through Reciprocal Targeting of HDAC2 in Osteoclasts and HDAC8 in T Cells , 2018, Front. Immunol..
[57] H. Blottière,et al. Butyrate produced by gut commensal bacteria activates TGF-beta1 expression through the transcription factor SP1 in human intestinal epithelial cells , 2018, Scientific Reports.
[58] S. Hazen,et al. Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential , 2018, Nature Medicine.
[59] Mingming Zhao,et al. Gut flora-dependent metabolite Trimethylamine-N-oxide accelerates endothelial cell senescence and vascular aging through oxidative stress. , 2018, Free radical biology & medicine.
[60] T. Kim,et al. Rediscover the clinical value of small intestinal bacterial overgrowth in patients with intestinal Behçet's disease , 2018, Journal of gastroenterology and hepatology.
[61] M. Mohajeri,et al. Probiotics and the Gut Immune System: Indirect Regulation , 2017, Probiotics and Antimicrobial Proteins.
[62] C. Lebrilla,et al. Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion , 2017, Science.
[63] W. Liao,et al. Influence of diet on the gut microbiome and implications for human health , 2017, Journal of Translational Medicine.
[64] Ashwin N Ananthakrishnan,et al. Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. , 2017, Cell host & microbe.
[65] Mingming Zhao,et al. Trimethylamine N-oxide in atherogenesis: impairing endothelial self-repair capacity and enhancing monocyte adhesion , 2017, Bioscience reports.
[66] S. Hazen,et al. Microbiome, trimethylamine N-oxide, and cardiometabolic disease. , 2017, Translational research : the journal of laboratory and clinical medicine.
[67] F. Cianchi,et al. Cytotoxic Th1 and Th17 cells infiltrate the intestinal mucosa of Behcet patients and exhibit high levels of TNF-α in early phases of the disease , 2016, Medicine.
[68] T. Ergun,et al. Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behçet's disease. , 2016, Clinical immunology.
[69] J. Shimizu,et al. Bifidobacteria Abundance-Featured Gut Microbiota Compositional Change in Patients with Behcet’s Disease , 2016, PloS one.
[70] Renan Corrêa-Oliveira,et al. Regulation of immune cell function by short-chain fatty acids , 2016, Clinical & translational immunology.
[71] S. Hazen,et al. Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk , 2016, Cell.
[72] S. Hazen,et al. Trimethylamine N‐Oxide Promotes Vascular Inflammation Through Signaling of Mitogen‐Activated Protein Kinase and Nuclear Factor‐κB , 2016, Journal of the American Heart Association.
[73] Michael A. Fischbach,et al. A biosynthetic pathway for a prominent class of microbiota-derived bile acids , 2015, Nature chemical biology.
[74] S. Rampelli,et al. Behçet's syndrome patients exhibit specific microbiome signature. , 2015, Autoimmunity reviews.
[75] L. Bergmeier,et al. The oral mucosal and salivary microbial community of Behçet's syndrome and recurrent aphthous stomatitis , 2015, Journal of oral microbiology.
[76] S. Kang,et al. Short chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway , 2014, Mucosal Immunology.
[77] S. Hazen,et al. γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. , 2014, Cell metabolism.
[78] Y. Belkaid,et al. Role of the Microbiota in Immunity and Inflammation , 2014, Cell.
[79] M. Tomita,et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells , 2013, Nature.
[80] J. Gordon,et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation , 2013, Proceedings of the National Academy of Sciences.
[81] E. Balskus,et al. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme , 2012, Proceedings of the National Academy of Sciences.
[82] Katherine H. Huang,et al. Structure, Function and Diversity of the Healthy Human Microbiome , 2012, Nature.
[83] P. Tontonoz,et al. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR , 2012, Nature Reviews Molecular Cell Biology.
[84] T. Karagiannis,et al. Histone Deacetylase Inhibition and Dietary Short-Chain Fatty Acids , 2011, ISRN allergy.
[85] Wei Sun,et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. , 2011, Cell metabolism.
[86] Brian J. Bennett,et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease , 2011, Nature.
[87] Stanley L Hazen,et al. Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease. , 2011, Clinical chemistry.
[88] B. M. Forman,et al. Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response , 2008, Hepatology.
[89] R Balfour Sartor,et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. , 2008, Cell host & microbe.
[90] T. Warner,et al. Farnesoid X Receptor Ligands Inhibit Vascular Smooth Muscle Cell Inflammation and Migration , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[91] Stefan Offermanns,et al. Activation of Platelet Function Through G Protein–Coupled Receptors Platelets As Immune Cells: Bridging Inflammation and Cardiovascular Disease In Vivo Thrombus Formation Platelet Adhesion Platelet Inhibitors and Thrombus Formation , 2006 .
[92] Dae-Joong Kang,et al. Bile salt biotransformations by human intestinal bacteria Published, JLR Papers in Press, November 18, 2005. , 2006, Journal of Lipid Research.
[93] W. Hörl,et al. Anti‐inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL‐12 and up‐regulation of IL‐10 production , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[94] D. Williamson,et al. Tissue and bacterial splitting of sulphasalazine. , 1983, Clinical science.